Request Sample
Request Methodology
Description
Molecular imaging Market size was valued at USD 4,206.0 million in 2021 and is projected to reach USD 4,214.0 million by 2028 at a CAGR of 5.4% during the forecast period 2022 to 2028. Molecular imaging is an innovative discipline in biomedical research, which facilitates visualizing, characterizing and quantifying the biological processes that takes place at cellular stage and sub cellular stages within intact living beings. The produced images from molecular imaging reflect the disease mechanisms, molecular pathways and cellular pathways of the disease that is present in the subject by in vivo and in vitro techniques. Molecular imaging enables help researches to gain better understanding of basic mechanisms underlying in cancers. Information that is provided by molecular imaging is way potential in development of drugs. Molecular imaging market has a lucrative growth due to advanced technologies like introduction of innovative molecular imaging devices with high and low magnetic field strengths. Moreover, expanding applications of molecular imaging in the breast cancer screening and neurological disorders such as Alzheimer’s disease and multiple sclerosis, spine and musculoskeletal injuries are expected to boost the molecular imaging market. Furthermore, market players are adopting strategies such as acquisitions and mergers, collaborations, and launching of newer devices are upsurge the revenue of Molecular Imaging Market. For instance, in July 2012, Aurora Imaging Technology, Inc. and SUMEC Group Corporation entered into a distribution agreement for expansion of breast MRI in China and in September 2016, GE Healthcare received market clearance for MAGiC (MAGnetic resonance image Compilation) software, a multi contrast MRI technique that delivers eight contrasts in a single acquisition in fraction of time of conventional imaging. In October 2017, Siemens Heathineers received FDA clearance for Magnetom Terra, a high field 7T MRI scanner. In November 2014, FUJIFILM Corporation entered into Positron Emission Tomography radiopharmaceuticals used in functional diagnosis of various cancers, neurological and heart diseases.
